Drilldown: Medicines
Medicines > classes 
:
Antidepressant or
Neuroleptic or
[[:Category:Mood_stabilizers|Mood stabilizer]]
:
Antidepressant or
Neuroleptic or
[[:Category:Mood_stabilizers|Mood stabilizer]] Use the filters below to narrow your results.
generic:
Agomelatine (1) ·
Amoxapine (1) ·
Asenapine (1) ·
Chlorpromazine (1) ·
Clomipramine (1) ·
Desipramine (1) ·
Droperidol (1) ·
Duloxetine (1) ·
Fluphenazine (1) ·
Iloperidone (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Levomilnacipran (1) ·
Loxapine (1) ·
Lurasidone (1) ·
Maprotiline (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Molindone (1) ·
Nefazodone (1) ·
Olanzapine / Fluoxetine (1) ·
Paliperidone (1) ·
Perphenazine (1) ·
Phenelzine (1) ·
Pimozide (1) ·
Protriptyline (1) ·
Reboxetine (1) ·
Sertraline (1) ·
Thioridazine (1) ·
Thiothixene (1) ·
Tianeptine (1) ·
Tranylcypromine (1) ·
Trifluoperazine (1) ·
Trimipramine (1) ·
Valproate (valproic acid, divalproex sodium, sodium valproate) (1) ·
Ziprasidone (1)
brand:
None (1) ·
Anafranil (1) ·
Aurorix (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Depakote, Depakote ER, Depakene, Depacon (IV) (1) ·
Edronax (1) ·
Fanapt (1) ·
Fetzima (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Ludiomil (1) ·
Marplan (1) ·
Mellaril (1) ·
Moban (1) ·
Nardil (1) ·
Navane (1) ·
Norpramin (1) ·
Orap (1) ·
Parnate (1) ·
Prolixin (1) ·
Saphris (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Stelazine (1) ·
Surmontil (1) ·
Symbyax (1) ·
Thorazine (1) ·
Tofranil (1) ·
Trilafon (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Phenothiazine D2 antagonist (4) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
Thioxanthene D2 antagonist (1) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1) ·
'"`UNIQ--vote-00000975-QINU`"' Hyperammonemic encephalopathy (consider in any unexplained CNS depression), thrombocytopenia, and polycystic ovary syndrome are characteristic chronic-use adverse effects beyond hepatic and pancreatic risks'"`UNIQ--ref-00000976-QINU`"'. (1) ·
'"`UNIQ--vote-00001549-QINU`"' Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard'"`UNIQ--ref-0000154A-QINU`"'. (1)
uses:
None (33) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
'"`UNIQ--vote-00000977-QINU`"', '"`UNIQ--vote-00000978-QINU`"', '"`UNIQ--vote-00000979-QINU`"', '"`UNIQ--vote-0000097A-QINU`"', '"`UNIQ--vote-0000097B-QINU`"' (1) ·
'"`UNIQ--vote-0000154B-QINU`"', '"`UNIQ--vote-0000154C-QINU`"' (1)
starting dose:
preparations:
None (33) ·
125, 250, 500 mg delayed-release tablets (Depakote); 250, 500 mg ER tablets (Depakote ER); 125, 250 mg sprinkle capsules; 250 mg/5 mL syrup; 500 mg IV (Depacon) (1) ·
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) ·
Capsules: 3/25, 6/25, 6/50, 12/25, 12/50 mg olanzapine/fluoxetine (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
None (32) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
Olanzapine 60% (oral); fluoxetine high (oral)'"`UNIQ--ref-0000154E-QINU`"' (1) ·
~100% (oral); highly (~90%) protein-bound, with non-linear binding above therapeutic levels (free fraction matters clinically in hypoalbuminemia)'"`UNIQ--ref-0000097D-QINU`"' (1) ·
~50% (highly variable) (1)
pregnancy:
None (32) ·
'''Contraindicated for migraine prophylaxis in pregnancy; high teratogenic risk''' (neural tube defects, craniofacial anomalies, cardiac defects, cognitive/IQ impairment); avoid in women of childbearing potential without reliable contraception when alternatives exist'"`UNIQ--ref-0000097E-QINU`"' (1) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (32) ·
Rx-only (1) ·
Rx-only in US (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries '''Boxed Warnings''' for hepatotoxicity (especially children <2 with metabolic disorders), teratogenicity, and pancreatitis'"`UNIQ--ref-0000097F-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly dementia patients'"`UNIQ--ref-0000154F-QINU`"' (1)
Showing below up to 36 results in range #1 to #36.